Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $26.89 down -6.86% from its previous closing price of $28.87. In other words, the price has decreased by -$6.86 from its previous closing price. On the day, 1.21 million shares were traded. CRNX stock price reached its highest trading level at $28.535 during the session, while it also had its lowest trading level at $26.48.
Ratios:
For a deeper understanding of Crinetics Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 23.04 and its Current Ratio is at 23.04. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 25, 2025, initiated with a Buy rating and assigned the stock a target price of $60.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 19 ’25 when Pizzuti Dana sold 2,515 shares for $34.20 per share. The transaction valued at 86,021 led to the insider holds 72,233 shares of the business.
Knight Jeff E. sold 7,162 shares of CRNX for $244,964 on Mar 19 ’25. The Chief Operating Officer now owns 87,491 shares after completing the transaction at $34.20 per share. On Mar 19 ’25, another insider, Betz Stephen F., who serves as the Chief Scientific Officer of the company, sold 5,770 shares for $34.20 each. As a result, the insider received 197,353 and left with 108,588 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2502074112 and an Enterprise Value of 1199728128. Its current Enterprise Value per Revenue stands at 1154.695 whereas that against EBITDA is -3.57.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.37, which has changed by -0.4209733 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $28.48. The 50-Day Moving Average of the stock is -23.74%, while the 200-Day Moving Average is calculated to be -43.95%.
Shares Statistics:
For the past three months, CRNX has traded an average of 1.07M shares per day and 1236190 over the past ten days. A total of 92.93M shares are outstanding, with a floating share count of 86.62M. Insiders hold about 6.91% of the company’s shares, while institutions hold 104.17% stake in the company. Shares short for CRNX as of 1741910400 were 7771573 with a Short Ratio of 7.26, compared to 1739491200 on 7796164. Therefore, it implies a Short% of Shares Outstanding of 7771573 and a Short% of Float of 8.51.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
